The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in proteinuria for IgAN, FSGS, and Alport syndrome patients receiving 0.75 mg atrasentan QD
Timeframe: Up to Week 12 or approximately 3 months
Change in albuminuria for DKD patients
Timeframe: Up to Week 12 or approximately 3 months
Change in proteinuria for FSGS patients at 1.5 mg dose
Timeframe: Up to Week 24 or approximately 6 months
Change in proteinuria for FSGS patients at 1.5 mg dose
Timeframe: Up to Week 30 or approximately 7.5 months